论文部分内容阅读
Purpose: To report on intraocular pressure (IOP) after intravitreal injections of triamcinolone acetonide. Design: Meta-analysis of previously reported data and case series studies. Participants: The study included 272 patients (305 eyes ) receiving an intravitreal injection of approximately 20 mg triamcinolone aceto nide as treatment for diffuse diabetic macular edema (n=84 patients), exudative age-related macular degeneration (n=181 patients), retinal vein occlusions (n=2 0 patients), uveitis (n=9), pseudophakic cystoid macular edema (n=6), and other reasons (n=5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0-35.7 months). Intervention: Intravitreal injection of approximately 20 mg t riamcinolone acetonide. Main Outcome Measure: Intraocular pressure. Results: Int raocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, r espectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5 .5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after in jection and returned to baseline values approximately 8 to 9 months after inject ion. Younger age (P=0.029)was significantly associated with triamcinolone-induc ed ocular hypertension. Triamcinolone responders and triamcinolone nonresponders did not vary significantly in gender (P=0.42), refractive error (P=0.86), diabe tes mellitus status (P=0.74), and reason for treatment. Conclusions: These findi ngs may be useful for comparing risks and benefits of intravitreal triamcinolone acetonide therapy.
Purpose: To report on intraocular pressure (IOP) after intravitreal injections of triamcinolone acetonide. Design: Meta-analysis of previously reported data and case series studies. Participants: The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg triamcinolone aceto nide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 2 0 patients), uveitis Mean follow-up was 10.4 ± 6.7 months (median, 7.9 months; range, 3.0-35.7 months). Intervention: Intravitreal injection of approximately 20 mg t riamcinolone (n = 6) acetonide. Main Outcome Measure: Intraocular pressure. Results: Int raocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, espectively, were measured in 112 (41.2% 15 (5.5%) patients, and 5 (1.8%) patients, res Trimecinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after in jection and returned to baseline values approximately 8 to 9 months after Innger age (P = 0.029) was significantly associated with triamcinolone-induc ed ocular hypertension. Triamcinolone responders and triamcinolone nonresponders did not vary significantly in gender (P = 0.42), refractive error (P = 0.86), diabe tes mellitus status (P = 0.74), and reason for treatment. Conclusions: These findings ngs may be useful for practices risks and benefits of intravitreal triamcinolone acetonide therapy.